Loading...

Clinical Trials

Home / Clinical Trials

Clinical Trials

Apellis is currently conducting clinical trials around the world for an array of autoimmune and inflammatory diseases, with its lead candidate APL-2, a complement C3 inhibitor. We believe that our approach has the potential to effectively control many complement-dependent diseases.

Learn more about Apellis-sponsored ongoing clinical trials below.

Disease

Autoimmune Hemolytic Anemia (AIHA)

Study

PLAUDIT Clinical Trial: A phase 2, prospective, open-label study to assess the safety, tolerability, preliminary efficacy, pharmacokinetics and pharmacodynamics of multiple doses of APL-2 in patients with autoimmune hemolytic anemia (AIHA).

This phase 2 clinical study of APL-2 for the treatment of AIHA is enrolling 12 patients across two cohorts; six patients in the in warm autoimmune hemolytic anemia (wAIHA) arm and six patients in the cold agglutinin disease (CAD) arm. For qualified patients who do not live near the study locations, Apellis will reimburse for costs associated with travel, if needed.

Status

Recruiting

Disease

Geographic Atrophy (GA)

Study

Our Phase 3 trials in Geographic Atrophy are scheduled to begin in the second half of 2018.

Status

Planned

Learn More

Email us at clinicaltrials@apellis.com.

Disease

Nephropathies

Study

DISCOVERY Clinical Trial: Phase 2 Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

Status

Recruiting

Learn More

clinicaltrials.gov

Disease

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study

PADDOCK Clinical Trial: Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of Subcutaneous APL-2 in PNH Subjects

Status

Recruiting

Learn More

clinicaltrials.gov

Disease

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study

PHAROAH Clinical Trial: A Phase I Study to Assess the Safety of APL-2 as an Add-On to Standard of Care in Subjects with PNH

Status

Active, not recruiting

Learn More

clinicaltrials.gov